Latest news
{{'2026-07-11T12:00:00Z' | dateFormatFilter}}
Novo Nordisk’s denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
{{'2026-06-26T13:01:00Z' | dateFormatFilter}}
Novo Nordisk to showcase new data across its haemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig
{{'2026-06-11T15:30:50Z' | dateFormatFilter}}
Novo Nordisk A/S: IT Security incident at Novo Nordisk
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
